Drug Trial Radar · NCT07649304
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 5, 2027
Primary completion
Dec 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in treating patients newly-diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific monoclonal antibody, which can bind to two different antigens that are expressed by cancer cells (CD3 and CD20) at the same time. This may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving glofitamab in combination with the R-CHOP regimen may be a safe treatment for patients with newly-diagnosed with HIV-associated large B-cell lymphoma.
Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8
- Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8
- Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8
- Plasmablastic Lymphoma
- Primary Effusion Lymphoma
Interventions
Biopsy ProcedureProcedure
Undergo tumor tissue biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy or aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy or aspiration
Computed TomographyProcedure
Undergo PET/CT
CyclophosphamideDrug
Given IV
Doxorubicin HydrochlorideDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
GlofitamabBiological
Given IV
Positron Emission TomographyProcedure
Undergo PET/CT
PrednisoneDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
RituximabBiological
Given IV
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ability to deliver at least 4 full cycles of glofitamab-rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (Glofit-RCHOP) (Feasibility)Time frame: Up to cycle 4 (Cycles = 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AIDS Malignancy Consortium
Rockville, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.